Please provide your email address to receive an email when new articles are posted on . Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers ...
Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...
Please provide your email address to receive an email when new articles are posted on . Among pregnant women who received nipocalimab infusions, 54% had live births without an intrauterine transfusion ...
Hemolytic disease of the newborn (HDN) secondary to anti-D has dramatically declined with the widespread prophylactic use of anti-D antibody preparation. Consequently, HDN attributed to other blood ...
InvestorsHub on MSN
HUTCHMED shares edge higher after Phase III success for sovleplenib in wAIHA
Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...
Dr. Alvin (Zip) Zipursky, a renowned specialist in pediatric hematology, and committed crusader for global health initiatives, played a pivotal role in one of the most dramatic advancements of ...
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older The first sickle hemoglobin polymerization inhibitor ...
The RhD (Rh 0 [D]) antigen is considered the most immunogenic of the antigens found on the surface of the human red cell. In 1941, Levine, Katzin, and Burham 1 showed that antibodies to the RhD ...
Hemolytic uremic syndrome (HUS) is a serious renal disease, and the most common etiologic factor in the development of acute renal failure in children. Most affected children are younger than 4 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback